Lesional ¹²⁴I SUV_max values in patients with vemurafenib-mediated RAI enhancement. Baseline and on therapy ¹²⁴I SUV_max values among the six patients with vemurafenib-induced enhancement of tumor RAI avidity are shown. Each data point represents one tumor before and after vemurafenib therapy. ¹²⁴I responders (red) are patients 2, 6, 7, and 11; ¹²⁴I nonresponders (blue) are patients 9 and 12.